Ferric Carboxymaltose Injection [Ferinject]

DRUG3 trials

Sponsors

Sichuan Huiyu Pharmaceutical Co., Ltd, Fundación para la Investigación del Hospital Clínico de Valencia, AFT Pharmaceuticals, Ltd.

Conditions

Acute Coronary Syndromes (ACS)AnaemiaElderly (People Aged 65 or More)Iron DeficienciesIron DeficiencyIron Deficiency Anemia (IDA)

Phase 1

Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia

CompletedNCT06080555

Sichuan Huiyu Pharmaceutical Co., LtdAnaemia, Iron Deficiency

Start: 2023-10-09End: 2024-03-22Updated: 2024-04-18

Phase 3

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

Not yet recruitingNCT07687784

AFT Pharmaceuticals, Ltd.Iron Deficiency Anemia (IDA)

Start: 2026-12-01End: 2028-07-01Target: 1366Updated: 2026-07-08

Phase 4

Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

RecruitingNCT07476859

Fundación para la Investigación del Hospital Clínico de ValenciaAcute Coronary Syndromes (ACS), Elderly (People Aged 65 or More), Iron Deficiencies

Start: 2026-03-05End: 2028-05-01Target: 538Updated: 2026-03-24